The Role of Cystatin C and Galectin-3 in Cardiorenal Syndrome

Abstract

Acute heart disease patients often go on to develop worsening renal function, termed as cardiorenal syndrome. The growing breadth of studies has shown the implications of combining multiple biomarkers to better chart outcomes between heart and kidneys, and produce desirable results in such patients, as cystatin C and galectin-3
 The aim: To estimate the levels of cystatin C and galectin-3, and their relationship with cardiorenal syndrome.
 Methods: Cystatin C and galectin-3 were obtained from 144 samples: 50 sample with cardiorenal syndrome, 25 sample with heart disease, 25 sample with kidney disease and 44 normal healthy .
 Results: A highly significant increase (p<0.0001) in the levels of cystatin C in serum of patients with cardirenal syndrome, heart disease and kidney disease compared with normal individuals. A highly significant (p<0.0001) increase in the serum levels of galectin-3 in patients with cardirenal syndrome and patients with heart disease, significant increase in the serum levels of galectin-3 and in patients with kidney disease when compared with control group
 Conclusions: Cystatin C and galectin-3 have higher diagnostic validity values in the current study, which may be useful as a diagnostic tool to identify recurrence of the cardiorenal syndromes